drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
A bispecific monoclonal antibody T‑cell engager (REGN5458) that binds BCMA on myeloma cells and CD3 on T cells to redirect CD3+ T cells to kill BCMA+ malignant plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Linvoseltamab (REGN5458) is a bispecific antibody that binds BCMA on multiple myeloma cells and CD3 on T cells, redirecting and activating CD3+ T cells to form cytolytic synapses and kill BCMA-expressing malignant plasma cells.
drug_name
Linvoseltamab
nct_id_drug_ref
NCT06669247